EPICS Global Perspectives: Current and Future State of CAR T

Virtual Meeting:
Monday, June 22, 2020 from 11am-1 pm EDT/ 5-7pm CET &
Wednesday, June 24, 2020 from 12-2pm EDT/ 6-8pm CET

THIS AGENDA AND ABSTRACT SELECTION ARE PRELIMINARY.
Discussion topics and selected abstracts may change depending on input from co-chairs and faculty

Co-Chairs: Marie José Kersten, MD, PhD (Netherlands) and Frederick Locke, MD (US)

Faculty:

- Catherine Thieblemont, MD, PhD (France)
- Martin Dreyling, MD (Germany) **TBC**
- Paolo Corradini, MD (Italy)
- Sattva Neelapu, MD (US)
- Jae Park, MD (US)
- Matthew Frigualt, MD (US)
- Hermann Einsele, MD (Germany) **TBC**

Virtual Meeting Part 1

Time	Topic	Speaker
10 min	**Introduction and Review of Agenda and Meeting Framework**	Marie José Kersten
	CAR T in DLBCL	
10 min	**Update on CAR T in DLBCL** • Brief review of new and relevant clinical advances in DLBCL including recently presented abstracts at ASCO and EHA	Paolo Corradini (TBD)
20 min	**Key Topics for Discussion** • Considering the (near) future approval of lisocabtagene maraleucel, what factors affect which CAR T construct would be prescribed, and why? • Moving CAR T up to second line or earlier – how feasible is this approach in DLBCL? What type of patients may be considered for CAR T in earlier lines? – Would CAR T ever displace HSCT in transplant-eligible patients? – Any updates on ongoing trials in that setting, such as ZUMA-7? • What is the feasibility of CAR T in elderly/frail patients? How do we define “frail” when it comes to CAR T? • Best bridging therapy (if any) for patients with DLBCL	All Discussion moderated by Fred Locke

	• Are there patient/disease characteristics in DLBCL predictive of response to CAR T-cell therapy? Are there predictors of toxicities? – How do these differ by patient subset (eg, second line and beyond transplant eligible vs third line and beyond)? • Where would advisors envision the position of bispecific antibodies relative to CAR T in DLBLC, and why? – Are bispecific antibodies approaching prime time in DLBCL? Which agents show the most promise, and why? Which ones are mostly ready? ▪ In your opinion, what is the most impactful data presented at ASCO and EHA on bispecific antibodies in DLBCL? – How does the durability of response and tolerability profile with bispecific antibodies compare with that of CAR T cells in patients with DLBCL? – Bispecific antibodies for patients who relapsed on CAR T – how promising is this approach considering responses appear to be similar to those seen with chemotherapy or single agents?	
5 min	**Summary of Key Takeaways: CAR T in DLBCL**	Marie José Kersten
CAR T in ALL		
10 min	**Update on CAR T in ALL** • Brief review of new and relevant clinical advances in ALL including recently presented abstracts at ASCO and EHA	Jae Park (TBD)
20 min	**Key Topics for Discussion** • Patient characteristics for CAR T-cell therapy • Is the efficacy of CAR T-cell therapy acceptable in more-heavily pretreated patients with ALL (eg, those who have received 3 or more previous therapies)? – Do advisors have a cutoff in terms of lines of therapy for considering a patient suitable? – Is there a role for CAR T as frontline therapy? • What is the role of CAR T-cell therapy in patients >25 years old with ALL? • How does MRD status affect treatment with CAR T? • How will the relationship between CAR T and HSCT evolve? – CAR T as bridge to HSCT or treatment option for patients who relapse following HSCT? – What type of patients may potentially benefit from HSCT after CAR T? – Role of HSCT or other consolidation in first-line therapy on the basis of MRD status	All Discussion moderated by Fred Locke

	• Competing or complementing treatment strategies – where do advisors see the positioning of bispecific antibodies relative to CAR T in ALL? Why?
	• In your opinion, what is the most impactful data presented at ASCO and EHA on bispecific antibodies in ALL?
	• CAR T vs bispecific antibodies: What disease- and therapy-related factors affect treatment selection (eg, durability of response, toxicity, activity in CNS disease)?
	  – How does the efficacy:toxicity ratio with bispecific antibodies compare with the profile of CAR T-cell therapy?
	• Toxicities of CAR T vs toxicities of bispecific antibodies – how to mitigate them, and how do they affect selection of treatment? Are there predictive factors for potential toxicities?
	• How much do logistics play a role in selecting CAR T vs bispecific antibodies, and why?
	  – Is off-the-shelf availability of bispecific antibodies a driver for use?	

5 min	**Summary of Key Takeaways: CAR T in ALL**	Fred Locke
CAR T in FL and MCL		
10 min	**Update on CAR T in FL and MCL** • Brief summary of latest advances in CAR T for FL and MCL including recently presented abstracts at ASCO and EHA	Martin Dreyling (TBD)

20 min	**Key Topics for Discussion**
	• How does CAR T efficacy in FL and MCL compare with results from DLBCL?
	• Are there patient/disease characteristics in FL and MCL predictive of response to CAR T cells? Are they different compared with DLBCL?
	• How to position CAR T in low-grade FL?
	• Combining CAR T with other agents in MCL such as ibrutinib? Acalabrutinib?
	• How comfortable are advisors with using CAR T-cell approaches in FL and MCL?
	• How will the potential approval of KTE-X19 impact the treatment landscape of MCL?
	  – How do advisors envision CAR T working in ibrutinib failure when treating MCL patients?
	• What response rates, duration of response, and indication can be expected from bispecific antibodies in FL and MCL?
	  – Which agents under investigation are the most promising?
		All
		
		Discussion moderated by Marie José Kersten

5 min	**Summary of Key Takeaways: CAR T in FL and MCL**	Fred Locke

5 min	**Closing remarks**	Marie José Kersten

Virtual Meeting Part 2

Time	Topic	Speaker
5 min	**Introduction and Review of Agenda and Meeting Framework**	Marie José Kersten
	Latest Clinical Pipeline and Emerging Indications	
10 min	**CAR T and Bispecific antibodies in MM** • Brief summary of latest advances in T-cell redirection strategies for MM including recently presented abstracts at ASCO and EHA	Hermann Einsele (TBD)
20 min	**Discussion: Current State and Future Directions in MM** Key Topics for Discussion • Are CAR T cells approaching prime time for MM? Which agents show the most promise? • Toxicities of bispecific antibodies, in particular neurotoxicities – how to mitigate them, and how do they affect selection of treatment? – What is the threshold of CRS that would be unacceptable for use of bispecific antibodies? – Requirement for inpatient treatment during the first days of initial infusion • Where do BCMA-directed strategies (CAR T and bispecific antibodies) best fit within the MM treatment landscape? Which patient population? • How would you choose between BCMA ADC vs bispecific antibody vs CAR T? Where would you see the different agents will be positioned in the treatment algorithm? For which patient? • Does failure to a BCMA-directed therapy prevent subsequent use of other BCMA-directed modalities? • Beyond BCMA – what are the most promising new targets? • MRD status in MM and how it might affect T-cell directed strategies • Dual-targeted CAR Ts – is this a viable approach for future investigations?	All Discussion moderated by Fred Locke
5 min	**Summary of Key Takeaways: Current State and Future Directions in MM**	Fred Locke
	The Path Forward	
15 min	**Discussion: The Next Frontier of CAR T Therapy – Development and Challenges** Key Topics for Discussion • Beyond CD19 – What are the most promising new targets? • CAR-based strategies beyond T lymphocytes – advances in alternative cell types (eg, NKT, NK, CIK)	All Discussion moderated by Fred Locke

	○ How to overcome challenges with NK cells (limited capacity to multiply and expand, short life span)? • How to minimize toxicities? • How to improve duration of response? • How to prevent resistance (eg, CD19 escape) and early loss of CAR T-cell persistence (eg, "booster" infusions with T-APCs [PLAT-03 study])? • How will the (near) future point-of-care CAR T production be positioned against centrally (commercially) manufactured CAR T cells? • Allogeneic CAR T – is this the future? Why or why not?	
5 min	**Discussion: T-Cell Therapy in Solid Tumors** Key Topics for Discussion • What are your impressions on T-cell therapies in development for solid tumors (eg, ADP-A2M4 SPEAR T cells)? • Based on your experience in hematology, what are the major challenges that you foresee for T cell therapy in solid tumor? • In your opinion, what are the shared key challenges between solid tumor and hematology when developing/using T cell therapy for clinical trials or practice?	All Discussion moderated by Fred Locke
5 min	**Summary of Key Takeaways: The Path Forward**	Fred Locke
CAR T in Times of COVID-19		
5 min	**Sharing Experiences: Impact of COVID-19 in Europe** • Sharing European experience on how COVID-19 has impacted the delivery of CAR T-cell therapy. More specifically – Top 3 major challenges and disruptions caused by the pandemic – Practical considerations and approaches on how to overcome these challenges/disruptions	Catherine Thieblemont (TBD)
5 min	**Sharing Experiences: Impact of COVID-19 in the US** • Sharing US experience on how COVID-19 has impacted the delivery of CAR T-cell therapy. More specifically – Top 3 major challenges and disruptions caused by the pandemic – Practical considerations and approaches on how to overcome these challenges/disruptions	Sattva Neelapu (TBD)
35 min	**Discussion: CAR T in times of COVID-19 and beyond** Key Topics for Discussion • How did COVID-19 impact your clinical practice for CAR T-cell therapy? What were the major challenges and disruptions caused by the pandemic regarding	All Discussion moderated by Marie José Kersten

	– Manufacturing – Logistics and shipping – Hospital and resource capacity – Apheresis and CAR T-cell therapy – Patient selection – Toxicity management – Flexibility of patient flow across different countries/states – Etc • Do you still face the same challenges/disruptions or are we slowly returning to 'normal'? If yes, what are these challenges/disruptions? • Impact on enrollment and continuation of clinical trials involving CAR T-cell therapies: What are the implications for patients and the community? • After COVID-19 – can we predict how this pandemic will impact the future of CAR T-cell therapy (eg, likely positioning, potential competitors)? – If so, what are 3 major expected changes for your practice in the future?	
5 min	**Summary of Key Takeaways: CAR T in times of COVID-19 and beyond**	Marie José Kersten
5 min	**Closing Remarks**	Marie José Kersten